 |
PDBsum entry 3d94
|
|
|
|
References listed in PDB file
|
 |
|
Key reference
|
 |
|
Title
|
 |
Small-Molecule inhibition and activation-Loop trans-Phosphorylation of the igf1 receptor.
|
 |
|
Authors
|
 |
J.Wu,
W.Li,
B.P.Craddock,
K.W.Foreman,
M.J.Mulvihill,
Q.S.Ji,
W.T.Miller,
S.R.Hubbard.
|
 |
|
Ref.
|
 |
Embo J, 2008,
27,
1985-1994.
[DOI no: ]
|
 |
|
PubMed id
|
 |
|
 |
 |
|
Abstract
|
 |
|
The insulin-like growth factor-1 receptor (IGF1R) is a receptor tyrosine kinase
(RTK) that has a critical role in mitogenic signalling during embryogenesis and
an antiapoptotic role in the survival and progression of many human tumours.
Here, we present the crystal structure of the tyrosine kinase domain of IGF1R
(IGF1RK), in its unphosphorylated state, in complex with a novel compound,
cis-3-[3-(4-methyl-piperazin-l-yl)-cyclobutyl]-1-(2-phenyl-quinolin-7-yl)-imidazo[1,5-a]pyrazin-8-ylamine
(PQIP), which we show is a potent inhibitor of both the unphosphorylated (basal)
and phosphorylated (activated) states of the kinase. PQIP interacts with
residues in the ATP-binding pocket and in the activation loop, which confers
specificity for IGF1RK and the highly related insulin receptor (IR) kinase. In
this crystal structure, the IGF1RK active site is occupied by Tyr1135 from the
activation loop of an symmetry (two-fold)-related molecule. This dimeric
arrangement affords, for the first time, a visualization of the initial
trans-phosphorylation event in the activation loop of an RTK, and provides a
molecular rationale for a naturally occurring mutation in the activation loop of
the IR that causes type II diabetes mellitus.
|
 |
|
|
|
|
 |